| Autor: |
Ashuro AA; Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China., Fan YG; Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China.; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, China., Fu YS; Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China., Di DS; Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China.; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, China., Sam NB; Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China., Pan HF; Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China.; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, China., Ye DQ; Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China.; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, China. |
| Abstrakt: |
Rosuvastatin therapy might have an effect on the inflammatory and coagulation biomarkers. However, the evidence about the effect of rosuvastatin therapy on the high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and D-dimer levels among people living with human immunodeficiency virus (PLHIV) is still unclear. Therefore, this study investigated the relational effect of rosuvastatin therapy on serum/plasma hsCRP, IL-6 and D-dimer levels in PLHIV. The literature search was done from Embase, PubMed, and Web of Science databases. The review and meta-analysis included studies written in English language up to January 4, 2020. Random effects model was used to evaluate the pooled standard mean difference with 95% confidence interval. A meta-analysis was performed using nine articles with 392 PLHIV. The result revealed that the plasma/serum levels of IL-6 were significantly reduced after the intervention. However, hsCRP and D-dimer levels showed no significant difference ( p > .05) between before and after the intervention. The subgroup analysis showed that there was significant association between PLHIV ages <45 years and cohort studies with IL-6 levels. The current CD4 + counts ≥350 cells/mm 3 correlated with hsCRP as well as IL-6. Similarly, nadir CD4 + counts ≥200 cells/mm 3 and duration of HIV diagnosis <10 years also showed significant association with IL-6 and D-dimer levels. It was also indicated that participants who were under antiretroviral drug for <7 years were significantly associated with hsCRP levels. This study established that IL-6 levels were significantly reduced after the intervention while hsCRP and D-dimer levels showed no significant difference between before and after the intervention. |
